O	0	5	Local
O	6	16	recurrence
O	17	19	in
O	20	26	breast
O	27	33	cancer
O	34	39	after
B-intervention	40	52	conservative
I-intervention	53	60	surgery
O	60	61	:
O	62	68	timing
O	69	71	of
O	72	84	radiotherapy
O	85	88	and
O	89	99	sequencing
O	100	102	of
O	103	115	chemotherapy
O	115	116	.

O	117	118	A
O	119	129	randomized
O	130	135	trial
O	136	139	was
O	140	149	conducted
O	150	152	to
O	153	162	determine
O	163	164	(
O	164	165	a
O	165	166	)
O	167	170	the
O	171	175	role
O	176	178	of
O	179	191	radiotherapy
O	192	195	and
O	196	208	chemotherapy
O	209	211	on
O	212	217	local
O	218	225	control
O	226	229	and
O	230	231	(
O	231	232	b
O	232	233	)
O	234	236	to
O	237	246	determine
O	247	250	the
O	251	257	timing
O	258	260	of
O	261	273	radiotherapy
O	274	277	for
B-eligibility	278	283	early
I-eligibility	283	284	-
I-eligibility	284	289	stage
I-eligibility	290	296	breast
I-eligibility	297	303	cancer
I-eligibility	303	304	.

B-intervention-participants	305	309	Five
I-intervention-participants	310	317	hundred
I-intervention-participants	318	321	and
I-intervention-participants	322	328	ninety
O	329	337	patients
O	338	342	were
O	343	350	treated
O	351	355	with
O	356	360	both
O	361	373	conservative
O	374	381	surgery
O	382	385	and
O	386	398	radiotherapy
O	399	400	(
O	400	405	group
O	406	407	A
O	407	408	)
O	408	409	.

O	410	413	The
O	414	421	average
O	422	426	time
O	427	435	interval
O	436	443	between
O	444	451	surgery
O	452	455	and
O	456	465	radiation
O	466	469	was
O	470	472	90
O	473	477	days
O	478	481	for
O	482	485	452
O	486	494	patients
O	495	498	and
O	499	503	over
O	504	506	90
O	507	511	days
O	512	515	for
O	516	519	138
O	520	528	patients
O	528	529	.

B-control-participants	530	533	One
I-control-participants	534	541	hundred
I-control-participants	542	545	and
I-control-participants	546	552	ninety
I-control-participants	552	553	-
I-control-participants	553	557	four
O	558	566	patients
O	567	576	underwent
B-control	577	585	adjuvant
I-control	586	593	therapy
O	594	599	based
O	600	602	on
O	603	606	CMF
O	607	615	regimens
O	616	617	(
O	617	622	group
O	623	624	B
O	624	625	)
O	625	626	.

O	627	632	Among
B-intervention-participants	633	636	396
O	637	645	patients
O	646	648	of
O	649	654	group
O	655	656	A
O	656	657	,
B-iv-bin-percent	658	659	8
I-iv-bin-percent	659	660	.
I-iv-bin-percent	660	661	1
I-iv-bin-percent	661	662	%
O	663	666	had
B-outcome	667	672	local
I-outcome	673	680	failure
O	680	681	;
O	682	684	we
O	685	693	observed
B-iv-bin-percent	694	695	7
I-iv-bin-percent	695	696	.
I-iv-bin-percent	696	697	2
I-iv-bin-percent	697	698	%
B-outcome	699	704	local
I-outcome	705	716	recurrences
O	717	719	in
B-intervention-participants	720	723	363
O	724	732	patients
O	733	736	who
O	737	745	received
O	746	753	therapy
O	754	760	before
O	761	763	90
O	764	768	days
O	769	772	and
B-iv-bin-percent	773	775	18
I-iv-bin-percent	775	776	.
I-iv-bin-percent	776	777	2
I-iv-bin-percent	777	778	%
O	779	781	in
O	782	790	patients
O	791	794	who
O	795	803	received
O	804	811	therapy
O	812	817	after
O	818	820	90
O	821	825	days
O	825	826	.

O	827	832	Among
O	833	841	patients
O	842	844	of
O	845	850	group
O	851	852	B
O	852	853	,
B-cv-bin-percent	854	855	7
I-cv-bin-percent	855	856	.
I-cv-bin-percent	856	857	7
I-cv-bin-percent	857	858	%
O	859	862	had
B-outcome	863	868	local
I-outcome	869	876	failure
O	876	877	;
O	878	881	for
O	882	890	patients
O	891	894	who
O	895	904	underwent
O	905	917	radiotherapy
O	918	924	before
O	925	927	90
O	928	932	days
O	932	933	,
O	934	937	the
B-outcome	938	943	local
I-outcome	944	954	recurrence
I-outcome	955	959	rate
O	960	963	was
B-cv-bin-percent	964	965	6
I-cv-bin-percent	965	966	.
I-cv-bin-percent	966	967	6
I-cv-bin-percent	967	968	%
O	968	969	,
O	970	978	compared
O	979	983	with
B-cv-bin-percent	984	986	12
I-cv-bin-percent	986	987	.
I-cv-bin-percent	987	988	3
I-cv-bin-percent	988	989	%
O	990	993	for
O	994	1002	patients
O	1003	1006	who
O	1007	1016	underwent
O	1017	1024	therapy
O	1025	1029	more
O	1030	1034	than
O	1035	1037	90
O	1038	1042	days
O	1043	1048	after
O	1049	1056	surgery
O	1056	1057	.

O	1058	1060	In
O	1061	1069	patients
O	1070	1073	who
O	1074	1077	are
O	1078	1086	eligible
O	1087	1089	to
O	1090	1097	receive
O	1098	1110	chemotherapy
O	1110	1111	,
O	1112	1114	it
O	1115	1117	is
O	1118	1126	possible
O	1127	1129	to
O	1130	1140	administer
O	1141	1153	radiotherapy
O	1154	1159	after
O	1160	1168	systemic
O	1169	1178	treatment
O	1178	1179	,
O	1180	1185	while
O	1186	1188	in
O	1189	1197	patients
O	1198	1201	who
O	1202	1206	have
O	1207	1209	to
O	1210	1212	be
O	1213	1220	treated
O	1221	1225	with
O	1226	1238	radiotherapy
O	1239	1243	more
O	1244	1248	then
O	1249	1251	90
O	1252	1256	days
O	1257	1262	after
O	1263	1269	breast
O	1270	1277	surgery
O	1277	1278	,
O	1279	1291	chemotherapy
O	1292	1295	can
O	1296	1302	reduce
O	1303	1306	the
O	1307	1312	local
O	1313	1320	failure
O	1321	1325	rate
O	1325	1326	.
